(Q51912115)

17 April 2018

title

A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment. (English)

1 reference

17 April 2018

author name string

Maria Johnson

1

1 reference

17 April 2018

Courtney Markham-Abedi

2

1 reference

17 April 2018

Margaret T Susce

3

1 reference

17 April 2018

Elaina Murray-Carmichael

4

1 reference

17 April 2018

Stuart McCollum

5

1 reference

17 April 2018

Jose de Leon

6

1 reference

17 April 2018

publication date

1 October 2006

1 reference

17 April 2018

published in

C N S Spectrums

1 reference

17 April 2018

volume

11

1 reference

17 April 2018

issue

10

1 reference

17 April 2018

page(s)

757-760

1 reference

17 April 2018

The dosing of atypical antipsychotics

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014887

Metabolic drug interactions with new psychotropic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014887

Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014887

Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014887

Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014887

Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014887

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014887

AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014887

Some aspects of genetic polymorphism in the biotransformation of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014887

Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014887

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014887

Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014887

Clinical pharmacokinetics of mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014887

inferred from DOI database lookup

7 January 2021

based on heuristic

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014887

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1017/S1092852900014887

1 reference

17 April 2018

1 reference

17 April 2018